Zobrazeno 1 - 10
of 69
pro vyhledávání: '"TOMOHIRO MIYAKE"'
Autor:
Yuki Asai, Yasushi Takai, Toshiki Murasaka, Tomohiro Miyake, Tomohisa Nakamura, Yoshihiko Morikawa, Yuji Nakagawa, Tatsuya Kanayama, Yasuharu Abe, Naoki Masuda, Yasushi Takamura, Yoshihiro Miki, Takuya Iwamoto
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-6 (2024)
Abstract Background Although pharmacists often identify numerous clinical questions, they face several barriers, including the lack of mentors for research activities in clinical settings. Therefore, a workshop for the appropriate selection of a stud
Externí odkaz:
https://doaj.org/article/b83db0c25a334c4cbe0692ea5b298846
Autor:
Sakina Hashizume, Masafumi Shimoda, Tetsuhiro Yoshinami, Kaori Abe, Nanae Masunaga, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Kenzo Shimazu
Publikováno v:
Surgical Case Reports, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Background Since humoral hypercalcemia of malignancy (HHM) in breast cancer patients without bone metastasis is rare, the clinical features of this condition are not fully understood. Case presentation During the recent 12 years, 3602 patien
Externí odkaz:
https://doaj.org/article/99f8a25b55544e639cc9a37f0bfcc515
Autor:
Kaori Abe, Masafumi Shimoda, Tetsuhiro Yoshinami, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Naofumi Kagara, Yasuto Naoi, Kenzo Shimazu
Publikováno v:
Surgical Case Reports, Vol 8, Iss 1, Pp 1-4 (2022)
Abstract Background Everolimus is a mechanistic-target-of-rapamycin (mTOR) inhibitor bearing a potent antitumor effect against hormone receptor-positive breast cancer. Here, we report the case of a patient with recurrent breast cancer who developed o
Externí odkaz:
https://doaj.org/article/eba388cc49fd4a3d90db9f002a36da61
Autor:
Yasufumi Sato, Masafumi Shimoda, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Naofumi Kagara, Yasuto Naoi, Seung Jin Kim, Shinzaburo Noguchi, Kenzo Shimazu
Publikováno v:
Cancer Medicine, Vol 10, Iss 4, Pp 1418-1430 (2021)
Abstract Humoral immunity plays a substantial role in the suppression of breast cancer. We have revealed that a high serum concentration of anti‐HER2 autoantibody (HER2‐AAb) is associated with favorable outcomes in patients with invasive breast c
Externí odkaz:
https://doaj.org/article/e1d0ef123b7e4c92a60cd01bbf3b7486
Autor:
Ami Hori, Masafumi Shimoda, Yasuto Naoi, Naofumi Kagara, Tomonori Tanei, Tomohiro Miyake, Kenzo Shimazu, Seung Jin Kim, Shinzaburo Noguchi
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-18 (2019)
Abstract Background Trastuzumab is a drug that targets the receptor tyrosine kinase HER2 and is essential for the treatment of HER2-positive breast cancer. Resistance to the drug leads to severe consequences, including disease recurrence, tumor enlar
Externí odkaz:
https://doaj.org/article/dc240d65806c4a55863e38adf2ed4150
Autor:
Seung Jin Kim, Yoshiaki Sota, Yasuto Naoi, Keiichiro Honma, Naofumi Kagara, Tomohiro Miyake, Masafumi Shimoda, Tomonori Tanei, Shigeto Seno, Hideo Matsuda, Shinzaburo Noguchi, Kenzo Shimazu
Publikováno v:
Translational Oncology, Vol 14, Iss 2, Pp 100986- (2021)
Recent studies demonstrated that homologous repair deficiency (HRD) score is a useful marker for response to poly (ADP-ribose) polymerase inhibitors or platinum-based chemotherapy. We determined HRD scores and elucidated the clinicopathologic charact
Externí odkaz:
https://doaj.org/article/fa955fe500804198917e330f2369ebd4
Autor:
Tetsuhiro Yoshinami, Naofumi Kagara, Daisuke Motooka, Shota Nakamura, Tomohiro Miyake, Tomonori Tanei, Yasuto Naoi, Masafumi Shimoda, Kenzo Shimazu, Seung Jin Kim, Shinzaburo Noguchi
Publikováno v:
Translational Oncology, Vol 13, Iss 8, Pp 100787- (2020)
We attempted to detect circulating tumor DNA (ctDNA), taking advantage of molecular barcode next-generation sequencing (MB-NGS), which can be more easily customized to detect a variety of mutations with a high sensitivity than PCR-based methods. Sequ
Externí odkaz:
https://doaj.org/article/dddc80bc73bf49589624688a637e2652
Autor:
Nanae Masunaga, Naofumi Kagara, Daisuke Motooka, Shota Nakamura, Tomohiro Miyake, Tomonori Tanei, Yasuto Naoi, Masafumi Shimoda, Kenzo Shimazu, Seung Jin Kim, Shinzaburo Noguchi
Publikováno v:
Translational Oncology, Vol 13, Iss 3, Pp - (2020)
ESR1 mutations in breast cancer are known as one of the mechanisms of resistance to aromatase inhibitors. These mutations often occur in the hotspot regions in the ligand binding domain (LBD), but comprehensive mutational analysis has shown that muta
Externí odkaz:
https://doaj.org/article/c60697c0f285477e86862e639d71fd03
Autor:
Ryuichi Kita, Natsuki Okai, Tomohiro Miyake, Yuya Fujiwara, Azusa Sakamoto, Hideyuki Komekado, Toru Kimura, Hiroyuki Marusawa
Publikováno v:
Kanzo. 64:74-77
Autor:
Kazunori Kurata, Yukio Nagata, Keisuke Oki, Keishi Ono, Tomohiro Miyake, Kaori Inui, Masashi Kobayashi
Publikováno v:
Physical Therapy Research; 2024, Vol. 27 Issue 1, p42-48, 7p